Tucatinib125mg

Tucatinib125mg Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Tucatinib125mg, Pharmacy / Drugstore, Tashkent.

Tukysa® (Tucatinib) — Generic Oncology MedicineTukysa® (Tucatinib) is a targeted anticancer medicine used in the treatme...
12/08/2026

Tukysa® (Tucatinib) — Generic Oncology Medicine

Tukysa® (Tucatinib) is a targeted anticancer medicine used in the treatment of certain HER2-positive cancers, including HER2-positive breast cancer, as part of combination therapy.

Generic: Tucatinib
Reference brand: Tukysa®
Therapeutic area: Oncology / HER2-targeted therapy

⚕️ Prescription medicine. Use only under the supervision of a qualified healthcare professional.

11/08/2026

Triko® — Cystic Fibrosis Treatment

Triko® contains a triple combination of CFTR modulators:

• Ivacaftor 75 mg
• Tezacaftor 50 mg
• Elexacaftor 100 mg

It is used for the treatment of Cystic Fibrosis (CF) in eligible patients with specific CFTR mutations.

Manufacturer: Beximco Pharmaceuticals Ltd., Bangladesh
Pack Size: 30 tablets
Prescription Medicine

For educational purposes only. Use prescription medicines only under the guidance of a qualified healthcare professional.

Triko® | Elexacaftor + Tezacaftor + IvacaftorTriko® contains Elexacaftor 100 mg + Tezacaftor 50 mg + Ivacaftor 75 mg and...
11/08/2026

Triko® | Elexacaftor + Tezacaftor + Ivacaftor

Triko® contains Elexacaftor 100 mg + Tezacaftor 50 mg + Ivacaftor 75 mg and belongs to the CFTR modulator class.

Uses:
Triko® is used in the treatment of cystic fibrosis (CF) in eligible patients with CFTR gene variants responsive to this combination. It works by helping improve the function of the CFTR protein.

Product Information:
💊 Brand: Triko®
🔬 Generic: Elexacaftor + Tezacaftor + Ivacaftor
💪 Strength: 100 mg + 50 mg + 75 mg
📦 Pack Size: 30 tablets
🏭 Manufacturer: Beximco Pharmaceuticals Ltd., Bangladesh
🔹 Original/Reference Brand: Trikafta®
🌍 Pharmaceutical Export

⚠️ Medical Disclaimer

This information is provided for educational and informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Triko® is a prescription medicine and should only be used under the direction and supervision of a qualified healthcare professional. Treatment suitability depends on the patient’s clinical condition and CFTR genotype.

Do not start, stop, or change any medication without consulting your doctor. Product availability, indications, dosage, and regulatory approval may vary by country. Always refer to the locally approved prescribing information.

Abemaciclib 150 mg – Educational InformationAbemaciclib is a CDK4/6 inhibitor used as part of treatment for certain type...
29/07/2026

Abemaciclib 150 mg – Educational Information

Abemaciclib is a CDK4/6 inhibitor used as part of treatment for certain types of HR-positive, HER2-negative advanced or metastatic breast cancer. Treatment decisions should always be made by a qualified oncologist based on the patient’s individual clinical condition.

This post is shared for medical education and professional awareness only. It is not an advertisement, offer for sale, or solicitation to purchase prescription medicine.

27/11/2025

Tucatinib is an oral targeted therapy used to treat HER2-positive metastatic breast cancer, including cases where the cancer has spread to the brain.
It works by blocking the HER2 signaling pathway, helping slow down the growth of cancer cells.

Tucatinib is usually taken together with trastuzumab and capecitabine, especially for patients who have already tried other HER2 treatments.
This combination can improve treatment response and delay cancer progression.

This medicine must be used under the supervision of an oncologist.

Tucatinib – Targeted Therapy for HER2-Positive Breast CancerTucatinib is an advanced targeted therapy used in combinatio...
27/11/2025

Tucatinib – Targeted Therapy for HER2-Positive Breast Cancer

Tucatinib is an advanced targeted therapy used in combination with other medicines to treat HER2-positive metastatic breast cancer, including cases that have spread to the brain (brain metastases).
It works by selectively blocking the HER2 signaling pathway, helping slow down cancer growth while keeping side-effects more manageable than many traditional treatments.

Key Points:
• Designed for HER2-positive breast cancer
• Often used with trastuzumab and capecitabine
• Can be effective even when previous HER2 treatments stop working
• Oral tablet — convenient for patients
• Helps improve progression-free survival and overall response.

02/11/2025

Tucatinib is a prescription medication primarily used in certain types of breast cancer. Here’s a clear breakdown:

1. Drug Class
• Type: Tyrosine kinase inhibitor (TKI)
• Target: HER2 (human epidermal growth factor receptor 2)
• Mechanism: Blocks the HER2 protein, which promotes growth of cancer cells.

2. Indications
• Used for HER2-positive breast cancer, especially:
• Metastatic (spread to other parts of the body)
• Often combined with other medications like trastuzumab and capecitabine
• Especially for patients with brain metastases from HER2-positive breast cancer, as it crosses the blood-brain barrier better than some other drugs.

3. How It’s Taken
• Oral tablet
• Usually taken twice daily, often with food
• Dose adjustment may be needed for liver problems.

4. Common Side Effects
• Diarrhea
• Hand-foot syndrome (redness, pain, or swelling on palms/soles)
• Fatigue
• Nausea or vomiting
• Liver enzyme elevation (requires monitoring)

5. Important Notes
• Should be used under strict medical supervision.
• Regular liver function tests are recommended.
• Often part of a combination therapy, not used alone.











19/10/2025

A next-generation EGFR inhibitor used for advanced non-small cell lung cancer (NSCLC) — including T790M-positive mutations.

Breast cancer therapy. Used in the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic bre...
18/10/2025

Breast cancer therapy. Used in the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, often in combination with:
• Fulvestrant or aromatase inhibitors (like letrozole, anastrozole, or exemestane), or
• As monotherapy (alone) if other endocrine therapies have failed.

⸻

💉 Dosage (typical adult):
• 150 mg twice daily (with fulvestrant or aromatase inhibitor)
• 200 mg twice daily (monotherapy)
• Taken with or without food
• Continue as long as patient benefits and no unacceptable toxicity occurs.

18/10/2025

💊 Abemaciclib (Verzenio) — advanced targeted therapy for HR-positive, HER2-negative breast cancer.
Helps stop cancer cell growth and improves survival outcomes.

🌿 Trusted oncology solution.



⸻

🧬 Detailed Version (for post or product description):

Abemaciclib (Verzenio) is an advanced CDK4/6 inhibitor used for hormone receptor-positive (HR+), HER2-negative breast cancer.
It targets cancer cells directly, slowing their growth and helping patients live longer with better quality of life.

✅ Used alone or with hormone therapy
✅ Improves survival in advanced breast cancer
✅ Global standard in targeted oncology treatme

Address

Tashkent

Website

Alerts

Be the first to know and let us send you an email when Tucatinib125mg posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Tucatinib125mg:

Shortcuts

Share

Category